S3 E3 - Melinda Bachini – Testing in Cholangiocarcinoma – Breaking Down Barriers
Release Date: 06/26/2023
S4 E3 - Courtney DiNardo, MD MSCE – Perspectives on AML
Karger - Fast Facts Oncology
This is the third episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management. In this episode, Dr. DiNardo discusses the missing pieces of MDS management, starting with the latest approvals in MDS treatment and how eligibility for clinical trials is assessed. She also touches on which impacts of transplantation or transformation to acute myeloid leukemia (AML) can be managed. She also touches on the cutting-edge genetic insights that might deliver on the promise of personalized medicine to MDS patients...
info_outline
S4 E2 - Elizabeth Griffiths, MD – Real World Evidence in Myelodysplastic Syndromes
Karger - Fast Facts Oncology
This is the second episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management. In this episode, Dr. Griffiths discusses what makes Real World Evidence and how it is obtained or archived, the risk stratification of MDS and what that means for gathering evidence, and bridging the gap between the best outcomes of clinical trials and the down-to-Earth results seen in daily clinical practice. For more podcast episodes from Karger please visit . This podcast was funded by Taiho Oncology, Inc. The faculty and...
info_outline
S4 E1 - Zachariah DeFilipp, MD – Emerging Treatment Paradigms in Myelodysplastic Syndromes
Karger - Fast Facts Oncology
This is the first episode in our series on myelodysplastic syndromes which aims to update clinicians on the latest developments in their diagnosis and management. In this episode, Dr. DeFilipp outlines the current and upcoming treatments for myelodysplastic syndromes. He discusses doublet and triplet combinations that are moving the needle on disease management, including emerging therapies and combinations of hypomethylating agents. He also considers which underlying mutations pose the greatest challenges and/or provide the greatest opportunities for future research in the field. For more...
info_outline
S3 E3 - Melinda Bachini – Testing in Cholangiocarcinoma – Breaking Down Barriers
Karger - Fast Facts Oncology
This is the third episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Melinda Bachini discusses the use of biomarker testing in cholangiocarcinoma. From the perspective of a patient advocate, she explains how to relay complex information about biomarker testing to patients, and outlines what patients really want to know. She provides advice on how to empower patients to navigate their diagnosis and be the best patient advocates they can possibly be. For more podcast episodes from Karger...
info_outline
S3 E2 - Marina Baretti, MD – Management of Safety When Using FGFR inhibitors
Karger - Fast Facts Oncology
This is the second episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Dr. Marina Baretti discusses the safety of fibroblast growth factor receptor (FGFR) inhibitors, drawing from her clinical experience. She details current safety data, and explains what you need to know about the management of their side effects and adverse events. For more podcast episodes from Karger please visit . This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely...
info_outline
S3 E1 - Sameek Roychowdhury, MD PhD – FGFR inhibitors: Mechanism and Activity on Resistance Mutations
Karger - Fast Facts Oncology
This is the first episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management. In this episode, Dr. Sameek Roychowdhury discusses fibroblast growth factor receptor (FGFR) inhibitors in the management of cholangiocarcinoma—how long they’ve been in use, and what we know about their efficacy and toxicity. He uses his clinical experience to share what clinicians really need to know about this treatment, and what to do when disease progresses while on this treatment. For more podcast episodes from Karger please visit ....
info_outline
S2 E3 - Ben George, MD – Perspectives on Real-World Data in Metastatic Colorectal Cancer
Karger - Fast Facts Oncology
This is the third episode in our series on colorectal cancer which aims to update clinicians on the latest developments in the management of colorectal cancer. In this episode, Dr. Ben George discusses the importance of real-world data in managing metastatic colorectal cancer care outcomes, and the inescapable truths of daily life that impact patient adherence and resilience. He explains how real-world data can be categorised as providing information on either the efficacy or toxicity of treatment, and how clinicians can use this data to guide management. For more podcast episodes from...
info_outline
S2 E2 - Reetu Mukherji, MD – Unmet Needs in Metastatic Colorectal Cancer
Karger - Fast Facts Oncology
This is the second episode in our series on colorectal cancer which aims to update clinicians on the latest developments in the management of colorectal cancer. In this episode, Dr. Reetu Mukherji discusses unmet needs in the treatment landscape of colorectal cancer. She explains where the greatest needs are in current management, and what research is being done to fill those gaps. Topics discussed include: adding checkpoint inhibitors to combinations and the use of novel molecules. Studies discussed include SEAMARK, TRIDENTE, BAYONET, MOUNTAINEER-03, STELLAR-303 among others. For more...
info_outline
S2 E1 - Arvind Dasari, MD MS – Emerging Treatments in Colorectal Cancer
Karger - Fast Facts Oncology
This is the first episode in our series on colorectal cancer which aims to update clinicians on the latest developments in treatment. In this episode, Dr. Arvind Dasari starts by explaining the current management of colorectal cancer, and then outlines the latest developments in immunotherapy and targeted therapies, touching on specific trials presented at ASCO GI 2023. Trials discussed include Phase III SUNLIGHT, Phase III Fresco-2 and PARADIGM. For more podcast episodes from Karger please visit . This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are...
info_outline
S1 E8 - Dr Hope Rugo – ESMO 2022 – Exploring the Latest Trial Data and Advances in Breast Cancer Treatments
Karger - Fast Facts Oncology
Welcome to the third episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer we speak with Dr Hope Rugo, Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Dr Rugo summarizes the TROPICS02 trial that she presented at this year's conference. We also discuss how data presented from the METEORA and ICON trials add to clinical understandings of immunotherapy response. Coverage is also provided to the ADAPT trial. Finally, we discuss how these clinical...
info_outlineThis is the third episode in our series on cholangiocarcinoma which aims to update clinicians on the latest developments in its diagnosis and management.
In this episode, Melinda Bachini discusses the use of biomarker testing in cholangiocarcinoma. From the perspective of a patient advocate, she explains how to relay complex information about biomarker testing to patients, and outlines what patients really want to know. She provides advice on how to empower patients to navigate their diagnosis and be the best patient advocates they can possibly be.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.